Understanding total body blood flow in patients with chest pain
Total Body Perfusion in Patients With Chest Pain
This study is trying to see how blocked arteries affect blood flow in different organs for patients with chest pain and suspected coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Turku University Hospital Government |
| Locations | 1 site (Turku) |
| Trial ID | NCT05825859 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate how obstructive coronary artery disease affects blood flow in various organs beyond the heart, such as the brain and kidneys. Patients experiencing chest pain and suspected coronary artery disease will undergo total body PET imaging using O15-water perfusion imaging to assess these changes. The observational nature of the study allows for a detailed analysis of perfusion patterns in relation to coronary artery health.
Who should consider this trial
Good fit: Ideal candidates include individuals with a documented history of chest pain and CT imaging indicating potential obstructive coronary artery disease.
Not a fit: Patients with certain cardiac conditions, such as second or third degree AV-block without a pacemaker or unstable acute myocardial infarction, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of coronary artery disease's impact on overall organ health, potentially leading to improved diagnostic and treatment strategies.
How similar studies have performed: While this approach is innovative, similar studies using advanced imaging techniques have shown promise in understanding coronary artery disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented history of chest pain with CT imaging showing a potential for obstructive coronary artery disease * Ability to sustain adenosine injection 0.14 mg/kg/min Exclusion Criteria: * Second or third degree AV-block without pacemaker * Sick sinus syndrome * Consumption of coffee or aminophylline within 12 hours of administration * Recent use of dipyridmole or dipyridamole-containing medications * Known hypersensitivity to adenosine * Unstable acute MI or acute coronary artery syndrome, and prior cardiac transplantation * Active wheezing and bronchospasm * Sinus bradycardia with HR\<40 bmp
Where this trial is running
Turku
- Turku University Hospital — Turku, Finland (Recruiting)
Study contacts
- Principal investigator: Juhani Knuuti, MD — Turku University Hospital
- Study coordinator: Juhani Knuuti, MD
- Email: juhani.knuuti@tyks.fi
- Phone: +358500592998
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.